ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "ea5d8dea-45a0-40b4-9062-87ca4ab2cbad"}, "_deposit": {"id": "2015716", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2015716"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02015716", "sets": ["1642838236563", "1642838412624"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "[\u539f\u8457\uff3d\u80ba\u764c\u306b\u5bfe\u3059\u308b Bleomycin + Adiamycin + ACNU(BAA) \u7642\u6cd5", "subitem_1551255648112": "ja"}, {"subitem_1551255647225": "Bleomycin-Adriamycin -ACNU (BAA) Combination Chemotherapy in Lung Cancer", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u5916\u9593, \u653f\u54f2", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "\u91d1\u57ce, \u52c7\u5fb3", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "\u4e45\u5834, \u7766\u592b", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "Hokama, Seitetsu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kinjoh, Yutoku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kuba, Mutsuo", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "ja", "subitem_1522651041219": "\u7409\u7403\u533b\u5b66\u4f1a"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Lung Cancer"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Bleomycin+Adriamycin+ ACNU"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Combination Chemotherapy"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "We report in this paper, on the combination chemotherapy with BLM-ADM-ACNU (BAA) in treatment of lung cancer. Nine cases with lung cancer, which were judged to be inoperable because of the advanced disease were treated with our newly devised BAA combination chemotherapy. Histologicaly they were confirmed having small cell cancer in one case, and squamous cell cancer in eight cases. The administration of the drugs was as follows; 100 mg of ACNU was given through i. v. infusion once to twice every four weeks up to 300 to 400 mg, and BLM, 15 mg twice a week for the first two weeks and then the same dosis once every following week up to 200 mg and ADM, 20 mg twice a week for the first two weeks and then the same dosis two weeks later up to 200 mg. One case with small cell cancer responded strikingly to the treatment showing complete response. In the cases with squamous cell cancer, partial response in one case, minor response in another case were observed, and the other six cases showed no change. These ineffective cases were rather poor in their performance stata having some serious complications such as SIADH, DIC and drug-induced exanthema, and so on, which might have had adversely influenced upon the result of the treatment. As to the side effects of the treatment, alopecia was the most common manifestation and bone marrow suppression was observed in two cases. Regarding with ACNU, it was concluded that after the first administration of 100 mg of ACNU, about four-week interval is necessary for the second administration because of a delayed myelosuppressive reaction. None of the cases manifested cardiotoxicity bnd pulmonary fibrosis.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "ja", "subitem_1522300316516": "\u7409\u7403\u5927\u5b66\u533b\u5b66\u90e8"}, {"subitem_1522300295150": "en", "subitem_1522300316516": "Faculty of Medicine, University of the Ryukyus"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "jpn"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "0289-1530"}, {"subitem_1522646500366": "NCID", "subitem_1522646572813": "AN10027430"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "ja", "subitem_1522650091861": "\u7409\u7403\u5927\u5b66\u533b\u5b66\u4f1a\u96d1\u8a8c : \u533b\u5b66\u90e8\u7d00\u8981 = Ryukyu medical journal"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueNumber": "1", "bibliographicPageEnd": "14", "bibliographicPageStart": "8", "bibliographicVolumeNumber": "8"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "v8p8.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2015716/files/v8p8.pdf"}, "version_id": "91084bcf-2891-4e5f-a3a6-b2f59e10f1bd"}]}, "item_title": "[\u539f\u8457\uff3d\u80ba\u764c\u306b\u5bfe\u3059\u308b Bleomycin + Adiamycin + ACNU(BAA) \u7642\u6cd5", "item_type_id": "15", "owner": "1", "path": ["1642838236563", "1642838412624"], "permalink_uri": "http://hdl.handle.net/20.500.12000/0002015716", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2010-06-30"}, "publish_date": "2010-06-30", "publish_status": "0", "recid": "2015716", "relation": {}, "relation_version_is_last": true, "title": ["[\u539f\u8457\uff3d\u80ba\u764c\u306b\u5bfe\u3059\u308b Bleomycin + Adiamycin + ACNU(BAA) \u7642\u6cd5"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. 琉球医学会
  3. 琉球大学医学会雑誌
  4. 8巻1号
  1. 部局別インデックス
  2. その他

[原著]肺癌に対する Bleomycin + Adiamycin + ACNU(BAA) 療法

http://hdl.handle.net/20.500.12000/0002015716
http://hdl.handle.net/20.500.12000/0002015716
818c4601-d65f-4369-9bd9-978a25560b3a
名前 / ファイル ライセンス アクション
v8p8.pdf v8p8.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2010-06-30
タイトル
タイトル [原著]肺癌に対する Bleomycin + Adiamycin + ACNU(BAA) 療法
言語 ja
作成者 外間, 政哲

× 外間, 政哲

ja 外間, 政哲

金城, 勇徳

× 金城, 勇徳

ja 金城, 勇徳

久場, 睦夫

× 久場, 睦夫

ja 久場, 睦夫

Hokama, Seitetsu

× Hokama, Seitetsu

en Hokama, Seitetsu

Kinjoh, Yutoku

× Kinjoh, Yutoku

en Kinjoh, Yutoku

Kuba, Mutsuo

× Kuba, Mutsuo

en Kuba, Mutsuo

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 ja
権利情報 琉球医学会
主題
言語 en
主題Scheme Other
主題 Lung Cancer
言語 en
主題Scheme Other
主題 Bleomycin+Adriamycin+ ACNU
言語 en
主題Scheme Other
主題 Combination Chemotherapy
内容記述
内容記述タイプ Other
内容記述 We report in this paper, on the combination chemotherapy with BLM-ADM-ACNU (BAA) in treatment of lung cancer. Nine cases with lung cancer, which were judged to be inoperable because of the advanced disease were treated with our newly devised BAA combination chemotherapy. Histologicaly they were confirmed having small cell cancer in one case, and squamous cell cancer in eight cases. The administration of the drugs was as follows; 100 mg of ACNU was given through i. v. infusion once to twice every four weeks up to 300 to 400 mg, and BLM, 15 mg twice a week for the first two weeks and then the same dosis once every following week up to 200 mg and ADM, 20 mg twice a week for the first two weeks and then the same dosis two weeks later up to 200 mg. One case with small cell cancer responded strikingly to the treatment showing complete response. In the cases with squamous cell cancer, partial response in one case, minor response in another case were observed, and the other six cases showed no change. These ineffective cases were rather poor in their performance stata having some serious complications such as SIADH, DIC and drug-induced exanthema, and so on, which might have had adversely influenced upon the result of the treatment. As to the side effects of the treatment, alopecia was the most common manifestation and bone marrow suppression was observed in two cases. Regarding with ACNU, it was concluded that after the first administration of 100 mg of ACNU, about four-week interval is necessary for the second administration because of a delayed myelosuppressive reaction. None of the cases manifested cardiotoxicity bnd pulmonary fibrosis.
内容記述タイプ Other
内容記述 論文
出版者
言語 ja
出版者 琉球大学医学部
言語
言語 jpn
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0289-1530
収録物識別子タイプ NCID
収録物識別子 AN10027430
収録物名
言語 ja
収録物名 琉球大学医学会雑誌 : 医学部紀要 = Ryukyu medical journal
書誌情報
巻 8, 号 1, p. 8-14
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-22 03:13:30.091836
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3